Prime Medicine, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, announced the appointment of Ann L. Lee, PhD, as Chief Technical Officer.

Dr. Lee will develop innovative CMC and manufacturing strategies, and oversee process and analytical development, supply chain, quality, and manufacturing operations in partnership with the company's research teams.

"I am very excited to help advance this groundbreaking technology to the clinic and move closer to helping patients suffering from serious diseases," said Lee. "I believe deeply in the power of teamwork to innovate powerful new medicines, so I am eager to join the great team at Prime. It is a true privilege to develop the technologies, capabilities, and infrastructure needed to advance Prime Editing therapeutics for patients."

Dr. Lee is an accomplished biotech executive with extensive experience in the development and manufacturing of engineered cell therapies, vaccines, biologics, and small molecule drugs. She led Technical Operations at Juno Therapeutics, which transitioned into leading roles at Celgene and then Bristol Myers Squibb. In those roles she built a global Cell Therapy Development and Operations organization responsible for developing new manufacturing processes and technologies, production, quality, facility design, global supply chain network, and digital systems to commercialize autologous, genetically engineered cell therapies.

"Ann is one of the absolute best in the business when it comes to manufacturing and process development for new therapeutic modalities, and we couldn't be happier to welcome her to Prime Medicine," said Keith Gottesdiener, MD, CEO of Prime Medicine. "Ann's passion for helping patients, developing talent, and advancing new technologies will make Prime an even more special place to work."